Key Insights

Highlights

Success Rate

67% trial completion

Treatment Research

4 treatments under study, led by Imatinib Mesylate

Research Leaders

5 sponsors active, led by University Diabetes & Endocrine Consultants

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 54/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

66.7%

-19.9% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results67% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
Phase 2 (1)
Phase 4 (1)

Trial Status

Completed2
Terminated1

Trial Success Rate

66.7%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT04591925Not ApplicableTerminated

SteadiSet™ Pilot Study (SteP Study)

NCT01781975Phase 2Completed

Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus

NCT00502138Phase 4CompletedPrimary

A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes

Showing all 3 trials

Research Network

Common Treatments

  • Imatinib Mesylate1
  • Investigative Insulin Infusion Devcie1
  • Control Device Insulin Infusion Devcie1
  • Pramlintide1

Active Sponsors

  • University Diabetes & Endocrine Consultants1
  • Juvenile Diabetes Research Foundation1
  • Amylin Pharmaceuticals, LLC.1
  • Capillary Biomedical, Inc.1
  • University of California, San Francisco1

Top Investigators

Related Conditions

  • Diabetes Mellitus Type I2
  • Diabetes Mellitus Insulindependent 12
  • Type 1 Diabetes Mellitus2
  • Type 1 Diabetes1
  • Insulindependent Diabetes Mellitus 11

Activity Timeline